<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05621408</url>
  </required_header>
  <id_info>
    <org_study_id>52002</org_study_id>
    <nct_id>NCT05621408</nct_id>
  </id_info>
  <brief_title>Attention Training Technique in Treatment of Anxiety and Depression in Coronary Heart Disease Patients</brief_title>
  <official_title>Attention Training Technique in Treatment of Anxiety and Depression in Coronary Heart Disease Patients -a Randomized Controlled Trial With 6 Months Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vestre Viken Hospital Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Hospital of Vestfold</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vestre Viken Hospital Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anxiety and depression are associated with work disability, lower participation rate in&#xD;
      cardiac rehabilitation and unfavourable life style changes following a coronary heart disease&#xD;
      (CHD) event. The prevalence of clinically significant symptoms of depression and anxiety in&#xD;
      CHD patients has been estimated to 30-50%. Furthermore, depression and anxiety are associated&#xD;
      with a significant increased risk of subsequent major adverse cardiovascular events and&#xD;
      mortality in CHD patients. Psychological interventions for anxiety and depression in CHD&#xD;
      patients have demonstrated small and uncertain effects of symptoms, and no effect on&#xD;
      cardiovascular outcomes. Therefore, testing the effectiveness of specific psychological&#xD;
      interventions that may affect central mechanisms for cardiovascular outcomes, has been&#xD;
      requested. The Attention training (ATT) Study is a randomized controlled trial comparing&#xD;
      group-attention training to wait-list control in 64 patients who experience significant&#xD;
      anxiety and depression after a CHD event. It will also be explored whether reduction in&#xD;
      psychological symptoms is correlated with changes in biological markers with a potential link&#xD;
      to cardiovascular outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2022</start_date>
  <completion_date type="Anticipated">December 20, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Hospital Anxiety and Depression -anxiety subscale score and Hospital Anxiety and Depression -depression subscale score</measure>
    <time_frame>Up to six weeks and six months after randomization</time_frame>
    <description>Changes in Hospital Anxiety and Depression -anxiety subscale score and Hospital Anxiety and Depression -depression subscale scores within and between the two treatment arms. Scores range 0-21, higher scores indicate more symptoms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Differences in proportion with Hospital Anxiety and Depression -anxiety and Hospital Anxiety and Depression-depression subscale scores &lt;8</measure>
    <time_frame>Up to six weeks and six months after randomization</time_frame>
    <description>Differences in proportion with Hospital Anxiety and Depression -anxiety subscale and Hospital Anxiety and Depression -depression subscale scores &lt;8 within and between the two treatment arms. Scores &gt;=8 indicate signicant symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in rumination scores</measure>
    <time_frame>Up to six weeks and six months after randomization</time_frame>
    <description>Changes in rumination scores assessed by the Ruminative Response scale within and between the two treatment arms. Scores range from 22-88, higher scores indicate more symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in worry scores</measure>
    <time_frame>Up to six weeks and six months after randomization</time_frame>
    <description>Changes in worry scores assessed by the Penn State Worry Questionnaire within and between the two treatment arms. Scores range 16-80, higher scores indicate more symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Positive Beliefs about Rumination Scale scores</measure>
    <time_frame>Up to six weeks and six months after randomization</time_frame>
    <description>Changes in Positive Beliefs about Rumination scores assessed by the Positive Beliefs about Rumination Questionnaire within and between the two treatment arms. Scores range 9-36, higher scores indicate stronger beliefs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Negative Beliefs about Rumination Scale scores</measure>
    <time_frame>Up to six weeks and six months after randomization</time_frame>
    <description>Changes in Negative Beliefs about Rumination scores assessed by the Negative Beliefs about Rumination Questionnaire within and between the two treatment arms. Scores range 13-52, higher scores indicate stronger beliefs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Metacognitions Questionnaire-30 scores</measure>
    <time_frame>Up to six weeks and six months after randomization</time_frame>
    <description>Changes in Metacognitions assessed by the Metacognitions Questionnaire-30 within and between the two treatment arms. Scores range 0-21, higher scores indicate more symptoms . Scores range 30-120, higher scores indicate stronger beliefs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in type d personality and its traits negative affectivity and social inhibition</measure>
    <time_frame>Up to six weeks and six months after randomization</time_frame>
    <description>Changes in type d personality and its traits negative affectivity and social inhibition assessed by the Distressed Scale (DS)-14 within and between the two treatment arms. Scores range 0-28, higher scores indicate more symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in quality of life</measure>
    <time_frame>Up to six weeks and six months after randomization</time_frame>
    <description>Changes in quality of life assessed by the Short Form (SF) 12 within and between the two treatment arms. Scores range 1-100, lower scores indicate lower quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Bergen Insomnia Scale scores</measure>
    <time_frame>Up to six weeks and six months after randomization</time_frame>
    <description>Changes in Bergen Insomnia Scale scores assessed by the Bergen Insomnia Scale within and between the two treatment arms. Scores range 0-42, higher scores indicate more symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in C-reactive Protein (CRP)</measure>
    <time_frame>Up to six weeks and six months after randomization</time_frame>
    <description>Changes in C-reactive Protein (CRP) measured in blood within and between the two treatment arms. Values range 0 to &gt;20, higher values indicate more subclinical inflammation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Depression, Anxiety</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Attention Training Techniqe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The treatment manual will consist of up to six weekly group sessions with 45-90 minutes duration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wait-list control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The wait-list control condition will not receive any psychological intervention during the six weeks waiting period. Subsequently, this group will also receive the intervention if the study entry criteria is still fulfilled</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Attention Training Technique</intervention_name>
    <description>Attention Training Technique is a six weeks psychological intervention provided by trained professionals</description>
    <arm_group_label>Attention Training Techniqe</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Established coronary heart disease as main somatic disease&#xD;
&#xD;
          -  &gt;=8 on either HADS-anxiety or depression subscale&#xD;
&#xD;
          -  Age 18 - 65 years&#xD;
&#xD;
          -  The ability to understand and speak Norwegian language,&#xD;
&#xD;
          -  Willingness and ability to give informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or past neurological illness&#xD;
&#xD;
          -  Traumatic brain injury&#xD;
&#xD;
          -  Current alcohol and/or substance dependency disorders&#xD;
&#xD;
          -  Psychotic disorders&#xD;
&#xD;
          -  Bipolar disorders&#xD;
&#xD;
          -  Developmental disorders&#xD;
&#xD;
          -  Mental retardation&#xD;
&#xD;
          -  Cognitive impairment which precludes informed consent/ability to participate&#xD;
&#xD;
          -  Acute suicidality&#xD;
&#xD;
          -  Life-expectancy less than 12 months&#xD;
&#xD;
          -  Concurrent psychological intervention for emotional distress&#xD;
&#xD;
          -  Antidepressant or anxiolytic medication initiated during previous 8 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>John Munkhaugen, MD,PhD</last_name>
    <phone>+4797524194</phone>
    <email>johmun@vestreviken.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Toril Dammen, MD,PhD</last_name>
    <phone>+4790163433</phone>
    <email>toril.dammen@medisin.uio.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital of Vestfold</name>
      <address>
        <city>TÃ¸nsberg</city>
        <state>Vestfold And Telemark County</state>
        <zip>3103</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kari H Peersen, MD, PhD</last_name>
      <email>kari.peersen@siv.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vestre Viken Trust Drammen hospital</name>
      <address>
        <city>Drammen</city>
        <state>Viken County</state>
        <zip>3004</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John D Munkhaugen, MD, PhD</last_name>
      <phone>+4797524194</phone>
      <email>johmun@vestreviken.no</email>
    </contact>
    <contact_backup>
      <last_name>Toril Dammen, MD, PhD</last_name>
      <phone>+4790163433</phone>
      <email>toril.dammen@medisin.uio.no</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>May 2023</verification_date>
  <study_first_submitted>November 2, 2022</study_first_submitted>
  <study_first_submitted_qc>November 9, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2022</study_first_posted>
  <last_update_submitted>May 2, 2023</last_update_submitted>
  <last_update_submitted_qc>May 2, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

